Neuromodulation Companies

The neuromodulation market is expected to grow from USD 6.81 billion in 2025 to USD 10.68 billion by 2030 with a CAGR of 9.4 %.

Neuromodulation is a medical technology that modifies nerve activity through precise stimulation of specific body areas. It encompasses a wide range of applications, from common management of chronic pain to treatments for neurological, urological, and movement disorders like Parkinson’s disease. By directly interacting with neural pathways, neuromodulation can restore functions, reduce symptoms, and enhance quality of life, with continuous advancements driving its rapid growth in modern medicine healthcare.

Notable companies in this market include Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US), among others. The leading companies in the market focus on higher sales, product launches, and product approvals.

To know about the assumptions considered for the study download the pdf brochure

Medtronic (Ireland)

Medtronic maintains a strong position in the neuromodulation market through its diverse and integrated product portfolio, combining organic innovation with strategic mergers and acquisitions to foster growth. Its consistent R&D investments—USD 2.74 billion in 2022, USD 2.69 billion in 2023, and USD 2.73 billion in 2024—demonstrate a continuous commitment to advancing technology and sustaining market leadership. Regulatory successes, such as the 2022 FDA approval of Intellis rechargeable neurostimulators for chronic pain related to diabetic peripheral neuropathy, along with strategic acquisitions, have further solidified its position. Medtronic’s global manufacturing footprint and strong clinician partnerships enable the delivery of tailored, cost-effective solutions with rapid adoption.

Boston Scientific Corporation (US)

Boston Scientific has built a strong position in the neuromodulation market with a diverse portfolio that includes advanced spinal cord stimulation (SCS) systems, such as WaveWriter Alpha, and deep brain stimulation (DBS) systems, supporting solutions for chronic pain and movement disorders. The company’s continuous innovation, extensive clinical programs, and strategic acquisition of Axonics, a key player in sacral neuromodulation, have further enhanced its market presence. By emphasizing product diversification and clinical validation, including presenting long-term efficacy data for its SCS neuromodulation at the 2022 North American Neuromodulation Society (NANS) meeting, Boston Scientific aims to expand indications and promote adoption of its neuromodulation devices solutions.

Abbott (US)

Abbott holds a prominent position in the neuromodulation market, supported by strong brand recognition and an extensive sales and distribution network. Its leadership is bolstered by a diverse portfolio of advanced neuromodulation systems, including spinal cord and deep brain stimulation technologies, along with a balanced strategy of organic innovation and strategic acquisitions to promote growth and competitiveness. Abbott’s strategic focus on innovation, global reach, and digital integration, combined with its strong presence across North America, Europe, and other regions through both direct and indirect channels, allows the company to offset regional demand fluctuations while maintaining a solid position in both developed and emerging markets.

Market Ranking

The neuromodulation market is led by major players such as Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), and Nevro Corp (US). Medtronic (Ireland) stands out with its neuromodulation solutions and strong R&D capabilities, enabling it to provide effective neuromodulation products. Boston Scientific Corporation (US) maintains its market position through strategic partnerships. Abbott (US) boosts its standing with global reach and new product launches. Competition in the market is fueled by innovative neuromodulation products and rising regulatory compliance requirements.

Related Reports:

Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com